Radiology:超低剂量CT透视在经皮穿刺介入手术的价值

2019-08-02 shaosai MedSci原创

本研究旨在验证超低剂量(ULD)CT透视在经皮CT引导下介入手术的可行性,比较传统CT与CT透视的放射剂量、空间定位准确性和金属伪影程度。

本研究旨在验证超低剂量(ULD)CT透视在经皮CT引导下介入手术的可行性,比较传统CT与CT透视的放射剂量、空间定位准确性和金属伪影程度。

对20只猪模型进行了20次手术操作,共包含246次传统CT扫描。利用仅2/984次传统CT方案进行模拟ULD CT荧光采集,定位和重建细针,并融合到已获得运动补偿CT扫描。比较ULD CT透视和传统CT检查对细针定位、放射剂量、金属伪影的差异。

结果为,利用传统CT和ULD CT透视下两者测量针尖的距离平均为1.06。与CT透视相比,经皮穿刺介入手术中患者和医师的评估放射剂量分别为0.99 mSv (减少21%) 、0.015 μGy (减少97%);金属伪影显着减少,运动校正平均误差为1-3 mm。

本研究表明,超低剂量CT透视具有降低经皮穿刺介入手术术中放射剂量,在保证图像质量的情况下减少金属伪影。

原始出处:

Wagner MG, Hinshaw JL, Li Y,et al.Ultra-Low Radiation Dose CT Fluoroscopy for Percutaneous Interventions: A Porcine Feasibility Study.Radiology.DOI:10.1148/radiol.2019181362

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2023246, encodeId=fd1b202324640, content=<a href='/topic/show?id=edd6e842119' target=_blank style='color:#2F92EE;'>#经皮穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78421, encryptionId=edd6e842119, topicName=经皮穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jun 26 18:09:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675523, encodeId=3a5416e552367, content=<a href='/topic/show?id=ff81252e49b' target=_blank style='color:#2F92EE;'>#介入手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25274, encryptionId=ff81252e49b, topicName=介入手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76627257106, createdName=yinhl1987, createdTime=Thu Feb 13 03:09:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370847, encodeId=75673e084778, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Aug 06 07:19:42 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311944, encodeId=89e1131194417, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423979, encodeId=423d14239e980, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480554, encodeId=bdb21480554c3, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2023246, encodeId=fd1b202324640, content=<a href='/topic/show?id=edd6e842119' target=_blank style='color:#2F92EE;'>#经皮穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78421, encryptionId=edd6e842119, topicName=经皮穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jun 26 18:09:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675523, encodeId=3a5416e552367, content=<a href='/topic/show?id=ff81252e49b' target=_blank style='color:#2F92EE;'>#介入手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25274, encryptionId=ff81252e49b, topicName=介入手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76627257106, createdName=yinhl1987, createdTime=Thu Feb 13 03:09:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370847, encodeId=75673e084778, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Aug 06 07:19:42 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311944, encodeId=89e1131194417, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423979, encodeId=423d14239e980, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480554, encodeId=bdb21480554c3, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2023246, encodeId=fd1b202324640, content=<a href='/topic/show?id=edd6e842119' target=_blank style='color:#2F92EE;'>#经皮穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78421, encryptionId=edd6e842119, topicName=经皮穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jun 26 18:09:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675523, encodeId=3a5416e552367, content=<a href='/topic/show?id=ff81252e49b' target=_blank style='color:#2F92EE;'>#介入手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25274, encryptionId=ff81252e49b, topicName=介入手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76627257106, createdName=yinhl1987, createdTime=Thu Feb 13 03:09:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370847, encodeId=75673e084778, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Aug 06 07:19:42 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311944, encodeId=89e1131194417, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423979, encodeId=423d14239e980, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480554, encodeId=bdb21480554c3, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=)]
    2019-08-06 thm112988

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2023246, encodeId=fd1b202324640, content=<a href='/topic/show?id=edd6e842119' target=_blank style='color:#2F92EE;'>#经皮穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78421, encryptionId=edd6e842119, topicName=经皮穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jun 26 18:09:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675523, encodeId=3a5416e552367, content=<a href='/topic/show?id=ff81252e49b' target=_blank style='color:#2F92EE;'>#介入手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25274, encryptionId=ff81252e49b, topicName=介入手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76627257106, createdName=yinhl1987, createdTime=Thu Feb 13 03:09:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370847, encodeId=75673e084778, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Aug 06 07:19:42 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311944, encodeId=89e1131194417, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423979, encodeId=423d14239e980, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480554, encodeId=bdb21480554c3, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=)]
    2019-08-04 rgjl
  5. [GetPortalCommentsPageByObjectIdResponse(id=2023246, encodeId=fd1b202324640, content=<a href='/topic/show?id=edd6e842119' target=_blank style='color:#2F92EE;'>#经皮穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78421, encryptionId=edd6e842119, topicName=经皮穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jun 26 18:09:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675523, encodeId=3a5416e552367, content=<a href='/topic/show?id=ff81252e49b' target=_blank style='color:#2F92EE;'>#介入手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25274, encryptionId=ff81252e49b, topicName=介入手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76627257106, createdName=yinhl1987, createdTime=Thu Feb 13 03:09:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370847, encodeId=75673e084778, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Aug 06 07:19:42 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311944, encodeId=89e1131194417, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423979, encodeId=423d14239e980, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480554, encodeId=bdb21480554c3, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2023246, encodeId=fd1b202324640, content=<a href='/topic/show?id=edd6e842119' target=_blank style='color:#2F92EE;'>#经皮穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78421, encryptionId=edd6e842119, topicName=经皮穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jun 26 18:09:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675523, encodeId=3a5416e552367, content=<a href='/topic/show?id=ff81252e49b' target=_blank style='color:#2F92EE;'>#介入手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25274, encryptionId=ff81252e49b, topicName=介入手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76627257106, createdName=yinhl1987, createdTime=Thu Feb 13 03:09:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370847, encodeId=75673e084778, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Aug 06 07:19:42 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311944, encodeId=89e1131194417, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423979, encodeId=423d14239e980, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480554, encodeId=bdb21480554c3, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Aug 04 13:09:00 CST 2019, time=2019-08-04, status=1, ipAttribution=)]

相关资讯

PLos One:使用离体肺模型在超低剂量CT中检测人工肺结节

在实际场景下进行的这个实验结果说明超低剂量CT用于检测肺结节的可行性。

Eur J Ophthalmol:玻璃体内注射超低剂量雷珠单抗治疗早产1型视网膜病变的疗效

埃及亚历山大亚历山大大学医学院眼科的Ahmed IS等人近日在Eur J Ophthalmol杂志上发表了一篇文章,他们报告了使用玻璃体内注射超低剂量雷珠单抗(0.1mg,0.01mL)治疗早产1型视网膜病变的结果。